KR20240149887A - 질환의 치료 및/또는 예방 방법에 사용되는 제제 - Google Patents

질환의 치료 및/또는 예방 방법에 사용되는 제제 Download PDF

Info

Publication number
KR20240149887A
KR20240149887A KR1020247025588A KR20247025588A KR20240149887A KR 20240149887 A KR20240149887 A KR 20240149887A KR 1020247025588 A KR1020247025588 A KR 1020247025588A KR 20247025588 A KR20247025588 A KR 20247025588A KR 20240149887 A KR20240149887 A KR 20240149887A
Authority
KR
South Korea
Prior art keywords
lipid
forty
formulation
twenty
thirty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247025588A
Other languages
English (en)
Korean (ko)
Inventor
볼커 페흐링
올리버 케일
외르그 카우프만
아칸크샤 모가
Original Assignee
판테르나 테라퓨틱스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 판테르나 테라퓨틱스 게엠베하 filed Critical 판테르나 테라퓨틱스 게엠베하
Publication of KR20240149887A publication Critical patent/KR20240149887A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247025588A 2022-02-14 2023-02-14 질환의 치료 및/또는 예방 방법에 사용되는 제제 Pending KR20240149887A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22156604.5A EP4226949A1 (en) 2022-02-14 2022-02-14 Preparation for use in a method for the treatment and/or prevention of a disease
EP22156604.5 2022-02-14
PCT/EP2023/053639 WO2023152398A1 (en) 2022-02-14 2023-02-14 Preparation for use in a method for the treatment and/or prevention of a disease

Publications (1)

Publication Number Publication Date
KR20240149887A true KR20240149887A (ko) 2024-10-15

Family

ID=80683166

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247025588A Pending KR20240149887A (ko) 2022-02-14 2023-02-14 질환의 치료 및/또는 예방 방법에 사용되는 제제

Country Status (8)

Country Link
US (1) US20240408014A1 (https=)
EP (2) EP4226949A1 (https=)
JP (1) JP2025505258A (https=)
KR (1) KR20240149887A (https=)
CN (1) CN118695875A (https=)
AU (1) AU2023217931A1 (https=)
CA (1) CA3243105A1 (https=)
WO (1) WO2023152398A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4681739A1 (en) 2024-07-19 2026-01-21 PROVIREX Genome Editing Therapies GmbH Lipid nanoparticles for direct delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119058A2 (en) * 2010-03-22 2011-09-29 Universidade De Coimbra F3-peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases
JP2018509387A (ja) * 2015-01-21 2018-04-05 フェーズアールエックス インコーポレイテッド 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
US20180200186A1 (en) * 2015-07-09 2018-07-19 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
EP3562510A4 (en) * 2016-12-30 2021-01-06 Genevant Sciences GmbH BRANCHED PEG MOLECULES AND ASSOCIATED COMPOSITIONS AND PROCEDURES

Also Published As

Publication number Publication date
EP4226949A1 (en) 2023-08-16
WO2023152398A1 (en) 2023-08-17
EP4479096A1 (en) 2024-12-25
AU2023217931A1 (en) 2024-07-18
CN118695875A (zh) 2024-09-24
JP2025505258A (ja) 2025-02-21
US20240408014A1 (en) 2024-12-12
CA3243105A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
JP2025173509A (ja) 核酸の送達のための改善された脂質ナノ粒子
CN110290812B (zh) 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
EP1764091B1 (en) Improvements in or relating to amphoteric liposomes
JP7370344B2 (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
KR101296326B1 (ko) 폴리락트산을 포함하는 음이온성 약물 전달용 조성물 및 그 제조 방법
WO2014089239A1 (en) Improved nucleic acid lipid particle formulations
AU2005306533A1 (en) siRNA silencing of apolipoprotein B
CN117545467A (zh) 含有核酸的纳米颗粒
EP3349730B1 (en) Systems for nucleic acid expression in vivo
CN1981044A (zh) 包封干扰rna的脂质
AU2023406321A1 (en) Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
Xu et al. Ligands located within a cholesterol domain enhance gene delivery to the target tissue
JP2025501905A (ja) イオン化脂質、脂質ナノ粒子、及びこれらの使用
KR20220140584A (ko) 내피로의 치료 활성제의 전달을 위한 지질 조성물 및 이의 용도
KR20240149887A (ko) 질환의 치료 및/또는 예방 방법에 사용되는 제제
US20260053944A1 (en) Cationic peptide/protein-modified exosomes for applications in drug delivery
US20070054873A1 (en) Glucocorticoid modulation of nucleic acid-mediated immune stimulation
WO2025090663A1 (en) Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
US20240417738A1 (en) Immunotherapies for the treatment of cancer
US20250235403A1 (en) Compositions and methods of the delivery of active agents including nucleic acids
KR20240072931A (ko) 히스티딘을 포함하는 지질 나노입자 및 그 제조방법
WO2023191050A1 (ja) がん送達用医薬組成物または免疫賦活用組成物
CN117460537A (zh) 核酸递送
KR20250092049A (ko) mRNA/LNP 백신의 면역원성 향상용 지질
CN120289333A (zh) 一种醇胺多尾脂质及其制备方法和应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201